Dr. Agarwal's Health Care Ltd. (AGARWALEYE) AI Stock Analysis

• Market Cap: ₹161.35B
• Dividend Yield: N/A
• Average Volume (3M): 110.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.46
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 4,214
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 316,158,360
• 10 Day Avg. Volume: 17,837
• 30 Day Avg. Volume: 110,853
• PEG Ratio: 43.43
• Price to Book (P/B): 7.19
• Price to Sales (P/S): 7.85
• P/FCF Ratio: 589.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: ₹604.00 ▲(10.40% Upside)

Dr. Agarwal's Health Care Ltd. demonstrates strong financial performance with significant revenue and profit growth, which is the most significant factor in the overall score. Technical analysis indicates positive momentum, though caution is advised due to overbought signals. The lack of valuation metrics introduces some uncertainty, slightly impacting the overall score.

Dr. Agarwal's Health Care Ltd. Business Overview & Revenue Model

Company Description

Dr. Agarwal's Health Care Ltd. (AGARWALEYE) is a leading healthcare provider in India, specializing in comprehensive eye care services. The company operates a network of eye hospitals and clinics, offering a wide range of ophthalmic treatments, including cataract surgeries, refractive surgeries, and other advanced eye care procedures. With a commitment to quality and accessibility, AGARWALEYE is dedicated to improving the vision health of its patients through state-of-the-art technology and experienced medical professionals.

How the Company Makes Money

AGARWALEYE generates revenue primarily through its clinical services, including consultations, diagnostic tests, and surgical procedures. The company's key revenue streams include fees charged for eye surgeries, outpatient consultations, and premium eye care packages. Additionally, AGARWALEYE may earn income through partnerships with health insurance providers, which can help cover costs for patients and increase patient volume. The company may also benefit from strategic alliances with pharmaceutical companies, enabling it to offer specialized treatments and medications, thereby enhancing its service offerings and boosting overall earnings.

Dr. Agarwal's Health Care Ltd. Financial Statement Overview

Summary

Dr. Agarwal's Health Care Ltd. presents a solid financial profile with strong revenue and profit growth, efficient operations, and healthy cash flow generation. The company should monitor debt levels despite a robust equity base.

Income Statement

Dr. Agarwal's Health Care Ltd. demonstrates strong revenue growth, with a substantial increase from 2022 to 2025. The gross profit margin is healthy, reflecting efficient cost management. The company has improved its EBIT and EBITDA margins over the years, indicating enhanced operational efficiency. However, the net profit margin shows some volatility, which could be due to fluctuating expenses or financing costs.

Balance Sheet

The balance sheet reveals a robust equity position with a growing stockholders' equity. The debt-to-equity ratio is moderately high, which suggests reliance on debt financing but is not alarming given the equity growth. Return on Equity (ROE) has improved, demonstrating effective use of equity to generate profits. However, the company should monitor its leverage to mitigate potential risks.

Cash Flow

Cash flow analysis shows consistent positive operating cash flow, supporting the company's operations and growth. The free cash flow has grown over the years, though there are fluctuations due to capital expenditures. The operating cash flow to net income ratio indicates strong cash generation relative to reported earnings, underscoring operational health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	17.88B	17.11B	13.32B	10.16B	6.95B
Gross Profit	9.07B	9.91B	3.85B	2.96B	1.91B
EBITDA	4.65B	4.99B	4.50B	2.84B	1.96B
Net Income	992.40M	834.60M	1.02B	940.97M	376.94M
Balance Sheet
Total Assets	0.00	36.72B	27.83B	18.25B	10.26B
Cash, Cash Equivalents and Short-Term Investments	5.13B	5.22B	5.87B	1.61B	996.21M
Total Debt	0.00	9.61B	9.68B	8.57B	6.19B
Total Liabilities	-19.27B	17.45B	13.89B	11.66B	7.92B
Stockholders Equity	19.27B	18.67B	13.48B	6.30B	2.12B
Cash Flow
Free Cash Flow	375.39M	227.90M	1.14B	753.05M	937.40M
Operating Cash Flow	1.01B	3.31B	3.46B	2.33B	1.64B
Investing Cash Flow	-2.22B	-7.54B	-9.14B	-5.09B	-1.55B
Financing Cash Flow	1.49B	4.14B	5.53B	3.03B	354.33M

Dr. Agarwal's Health Care Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AGARWALEYE	―	₹161.35B	―	―	―	―	―
MARKSANS	―	₹80.16B	22.89	―	0.43%	16.94%	4.90%
HCG	―	₹103.33B	275.51	―	―	16.85%	-29.57%
JLHL	―	₹102.21B	52.40	―	0.13%	18.34%	15.25%
RAINBOW	―	₹141.02B	54.30	―	0.22%	14.82%	19.38%
METROPOLIS	―	₹98.98B	64.71	―	―	12.86%	10.42%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Dr. Agarwal's Health Care Ltd. Corporate Events

Dr. Agarwal’s Health Care Expands Stake in Eye Hospital Subsidiary

Dr. Agarwal’s Health Care Ltd. has increased its stake in Dr. Agarwal’s Eye Hospital Limited to 72.67% by acquiring 132,827 equity shares at INR 5,270 each. This acquisition strengthens the company’s control over its eye care operations, potentially enhancing its market position and influence in the healthcare sector.

Dr. Agarwal’s Health Care and Eye Hospital Announce Strategic Merger

Dr. Agarwal’s Health Care Limited and Dr. Agarwal’s Eye Hospital Limited have announced a merger to streamline operations and enhance strategic alignment. The merger aims to create value for stakeholders by consolidating resources, improving operational and financial efficiencies, and providing a stronger balance sheet to support future growth. The transaction is expected to be EPS accretive from the first year and will not affect the public shareholding of the merged entity.

Dr. Agarwal’s Health Care Announces Analyst Call on Proposed Merger

Dr. Agarwal’s Health Care Limited has announced an analyst call to discuss the proposed merger with its subsidiary, Dr. Agarwal’s Eye Hospital Limited. This merger, approved by the Board of Directors, is expected to enhance the company’s operational efficiency and market positioning in the eye care sector.

Dr. Agarwal’s Health Care Ltd. Announces Strategic Merger

Dr. Agarwal’s Health Care Ltd. has announced a proposed merger with Dr. Agarwal’s Eye Hospital Ltd. This strategic move is expected to enhance the company’s operational capabilities and strengthen its position in the eye care sector, potentially benefiting stakeholders by expanding service offerings and market reach.

Dr. Agarwal’s Health Care Releases Q1 Monitoring Report Post-IPO

Dr. Agarwal’s Health Care Ltd. has released its Monitoring Agency Report for the quarter ended June 30, 2025, prepared by ICRA Limited. This report, in compliance with SEBI regulations, details the utilization of proceeds from the company’s Initial Public Offer. While the report does not assess the quality or outcomes of the spending, it is a crucial document for stakeholders to understand the financial management and strategic direction of the company following its IPO.